Compare Illumina, Inc. (ILMN) vs Synchrony Financial (SYF) Price & Performance

Illumina, Inc.Trade

Synchrony FinancialTrade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs Synchrony Financial — how do they compare? Illumina, Inc. trades at $192.8 (market cap $27.94B), while Synchrony Financial trades at $71.7 (market cap $24.69B). The key difference: Illumina, Inc. and Synchrony Financial are close in size by market cap, and Synchrony Financial pays a 1.63% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.

	ILMN	SYF
Market Cap	$27.94B	$24.69B
Sector	Health	Financials
52-Week High	$194.33	$88.47
52-Week Low	$91.00	$63.78
Enterprise Value	$29.33B	—
Dividend Yield	—	1.63%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.

Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.

Synchrony Financial

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ILMN

ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026.24/7 Wall Street · 14 hours agoNeutral Cancer biomarkers market to hit $54.48B by 2032, driven by tech advances and Asia-Pacific growthResearchandmarkets.Com · 4 days agoBullish New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral View details →

SYF

Synchrony Financial shares fall despite strong loan growth and attractive dividends.Seeking Alpha · 5 hours agoBullish Consumers keep spending frequently despite inflation, boosting Synchrony's Q2 purchase volume 8%.PYMNTS · 9 hours agoBullish Synchrony Financial declares $0.34 quarterly dividend per common share, payable August 17, 2026.PRNewsWire · 17 hours agoNeutral View details →

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

About Synchrony Financial

Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.